Homo sapiens Protein: ISG15 | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Summary | |||||||||||||||||||||||||||||
InnateDB Protein | IDBP-84314.6 | ||||||||||||||||||||||||||||
Last Modified | 2014-10-13 [Report errors or provide feedback] | ||||||||||||||||||||||||||||
Gene Symbol | ISG15 | ||||||||||||||||||||||||||||
Protein Name | ISG15 ubiquitin-like modifier | ||||||||||||||||||||||||||||
Synonyms | G1P2; hUCRP; IFI15; IP17; UCRP; | ||||||||||||||||||||||||||||
Species | Homo sapiens | ||||||||||||||||||||||||||||
Ensembl Protein | ENSP00000368699 | ||||||||||||||||||||||||||||
InnateDB Gene | IDBG-84312 (ISG15) | ||||||||||||||||||||||||||||
Protein Structure | |||||||||||||||||||||||||||||
UniProt Annotation | |||||||||||||||||||||||||||||
Function | Ubiquitin-like protein which plays a key role in the innate immune response to viral infection either via its conjugation to a target protein (ISGylation) or via its action as a free or unconjugated protein. ISGylation involves a cascade of enzymatic reactions involving E1, E2, and E3 enzymes which catalyze the conjugation of ISG15 to a lysine residue in the target protein. Its target proteins include IFIT1, MX1/MxA, PPM1B, UBE2L6, UBA7, CHMP5, CHMP2A, CHMP4B and CHMP6. Can also isgylate: EIF2AK2/PKR which results in its activation, DDX58/RIG-I which inhibits its function in antiviral signaling response, EIF4E2 which enhances its cap structure-binding activity and translation- inhibition activity, UBE2N and UBE2E1 which negatively regulates their activity, IRF3 which inhibits its ubiquitination and degradation and FLNB which prevents its ability to interact with the upstream activators of the JNK cascade therby inhibiting IFNA- induced JNK signaling. Exhibits antiviral activity towards both DNA and RNA viruses, including influenza A, HIV-1 and Ebola virus. Restricts HIV-1 and ebola virus via disruption of viral budding. Inhibits the ubiquitination of HIV-1 Gag and host TSG101 and disrupts their interaction, thereby preventing assembly and release of virions from infected cells. Inhibits Ebola virus budding mediated by the VP40 protein by disrupting ubiquitin ligase activity of NEDD4 and its ability to ubiquitinate VP40. ISGylates influenza A virus NS1 protein which causes a loss of function of the protein and the inhibition of virus replication. The secreted form of ISG15 can: induce natural killer cell proliferation, act as a chemotactic factor for neutrophils and act as a IFN-gamma-inducing cytokine playing an essential role in antimycobacterial immunity. {ECO:0000269PubMed:1373138, ECO:0000269PubMed:16009940, ECO:0000269PubMed:16112642, ECO:0000269PubMed:16428300, ECO:0000269PubMed:16434471, ECO:0000269PubMed:16872604, ECO:0000269PubMed:18305167, ECO:0000269PubMed:19270716, ECO:0000269PubMed:19357168, ECO:0000269PubMed:2005397, ECO:0000269PubMed:20133869, ECO:0000269PubMed:20308324, ECO:0000269PubMed:20639253, ECO:0000269PubMed:21543490, ECO:0000269PubMed:22693631, ECO:0000269PubMed:22859821, ECO:0000269PubMed:23229543, ECO:0000269PubMed:7526157, ECO:0000269PubMed:8550581}. | ||||||||||||||||||||||||||||
Subcellular Localization | Cytoplasm {ECO:0000269PubMed:22859821}. Secreted {ECO:0000269PubMed:22859821}. Note=Exists in three distinct states: free within the cell, released into the extracellular space, or conjugated to target proteins. | ||||||||||||||||||||||||||||
Disease Associations | |||||||||||||||||||||||||||||
Tissue Specificity | Detected in lymphoid cells, striated and smooth muscle, several epithelia and neurons. Expressed in neutrophils, monocytes and lymphocytes. Enhanced expression seen in pancreatic adenocarcinoma, endometrial cancer, and bladder cancer, as compared to non-cancerous tissue. In bladder cancer, the increase in expression exhibits a striking positive correlation with more advanced stages of the disease. {ECO:0000269PubMed:22859821, ECO:0000269PubMed:7490683}. | ||||||||||||||||||||||||||||
Comments | |||||||||||||||||||||||||||||
Interactions | |||||||||||||||||||||||||||||
Number of Interactions |
This gene and/or its encoded proteins are associated with 244 experimentally validated interaction(s) in this database.
They are also associated with 5 interaction(s) predicted by orthology.
|
||||||||||||||||||||||||||||
Gene Ontology | |||||||||||||||||||||||||||||
Molecular Function |
|
||||||||||||||||||||||||||||
Biological Process |
|
||||||||||||||||||||||||||||
Cellular Component |
|
||||||||||||||||||||||||||||
Protein Structure and Domains | |||||||||||||||||||||||||||||
PDB ID | |||||||||||||||||||||||||||||
InterPro |
IPR000626
Ubiquitin-like IPR019956 Ubiquitin IPR029071 Ubiquitin-related domain |
||||||||||||||||||||||||||||
PFAM |
PF00240
PF14560 |
||||||||||||||||||||||||||||
PRINTS |
PR00348
|
||||||||||||||||||||||||||||
PIRSF | |||||||||||||||||||||||||||||
SMART |
SM00213
|
||||||||||||||||||||||||||||
TIGRFAMs | |||||||||||||||||||||||||||||
Post-translational Modifications | |||||||||||||||||||||||||||||
Modification | |||||||||||||||||||||||||||||
Cross-References | |||||||||||||||||||||||||||||
SwissProt | P05161 | ||||||||||||||||||||||||||||
PhosphoSite | PhosphoSite-P05161 | ||||||||||||||||||||||||||||
TrEMBL | |||||||||||||||||||||||||||||
UniProt Splice Variant | |||||||||||||||||||||||||||||
Entrez Gene | 9636 | ||||||||||||||||||||||||||||
UniGene | |||||||||||||||||||||||||||||
RefSeq | NP_005092 | ||||||||||||||||||||||||||||
HUGO | HGNC:4053 | ||||||||||||||||||||||||||||
OMIM | 147571 | ||||||||||||||||||||||||||||
CCDS | CCDS6 | ||||||||||||||||||||||||||||
HPRD | 00958 | ||||||||||||||||||||||||||||
IMGT | |||||||||||||||||||||||||||||
EMBL | AL645608 AY168648 BC009507 BT007297 CH471183 M13755 M21786 | ||||||||||||||||||||||||||||
GenPept | AAA36038 AAA36128 AAH09507 AAN86983 AAP35961 CAI15574 EAW56295 | ||||||||||||||||||||||||||||